Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neogen Corporation (NEOG) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Neogen’s operations in food safety, animal safety, and related markets, as well as its governance, compensation practices, and financial condition.
Neogen uses current reports on Form 8-K to disclose material events such as the appointment of a new President and Chief Executive Officer, changes in the Chief Financial Officer role, director retirements and appointments, and the results of shareholder votes at its annual meeting. Filings describe executive compensation arrangements, including base salary, annual bonus targets, long-term equity incentives, and performance share unit programs tied to metrics like revenue growth, adjusted EBITDA margin expansion, and cash flow conversion.
Investors can also review 8-K filings that furnish earnings press releases, which summarize quarterly and annual results, segment performance for Food Safety and Animal Safety, and non-GAAP measures such as adjusted EBITDA. These filings complement the company’s financial statements by providing narrative context and reconciliations.
On Stock Titan, NEOG filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key elements of lengthy documents, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Users can quickly identify disclosures related to executive and director changes, incentive plans, shareholder meeting outcomes, and other governance matters.
This page is a resource for understanding how Neogen describes its strategy, risk factors, performance metrics, and capital structure in its own words through formal SEC filings, with tools to make complex regulatory content more accessible.
David H. Naemura, identified as an officer (CFO) and director, reported insider purchases for NEOG on 08/15/2025. He acquired 230,203 shares of Neogen common stock at $5.43 per share, bringing his total beneficial ownership to 291,637 shares. The filing also reports derivative securities: 591,690 rights/options to buy common stock with a $5.43 exercise price, acquired 08/15/2025 and exercisable immediately, expiring 08/15/2035. The disclosure states the options vest in equal annual installments over the first three anniversaries and that performance stock units vest in full at the three-year anniversary. The form was signed by an attorney-in-fact on 08/19/2025.
Amy M. Rocklin, Chief Legal Officer of Neogen Corp (NEOG), reported equity awards and option grants that increase her direct ownership. She acquired 119,705 common shares at $5.43 per share, bringing her direct beneficial ownership to 156,556 shares. In addition, she received a derivative award giving the right to buy 307,680 shares at an exercise price of $5.43, exercisable through 08/15/2035.
The filing notes the option grants vest in equal annual installments over the first three anniversaries of the grant and that performance stock units vest in full at the three-year anniversary. All reported holdings are direct ownership.
Neogen Corp insider filing: John Patrick Moylan, identified as a director and Chief Accounting Officer, reported purchases on 08/15/2025. He acquired 18,416 shares of NEOG common stock at a price of $5.43 per share, bringing his total reported beneficial ownership to 31,371 shares. The filing also reports acquisition of derivative rights described as the right to buy 47,336 shares at a $5.43 exercise price, exercisable beginning 08/15/2025 and expiring 08/15/2035, with 47,336 underlying shares shown as beneficially owned following the transaction. The filing notes that options and restricted stock units vest in equal annual installments on each of the first three anniversary dates of the grants.
Nassif Mikheal, identified as CEO and a director of Neogen Corp (NEOG), reported multiple acquisitions on 08/15/2025. He acquired 184,162 shares of common stock and 414,365 shares of common stock at $5.43 per share, leaving 598,527 shares beneficially owned after the transactions. He also acquired derivative rights (options/RSU/PSU grants) exercisable into 1,065,042 and 473,352 shares with an exercise/conversion price of $5.43 and expiration/vesting noted as 08/15/2035. The filing includes vesting schedule notes: some options/RSUs vest over three years, others over four years, and PSUs vest in total at the three-year anniversary. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Nassif Mikheal, identified as Chief Executive Officer, submitted an initial Form 3 reporting his relationship to Neogen Corp (NEOG).
The filing states that no securities are beneficially owned by the reporting person. The form was filed by a single reporting person and bears a signature executed by an attorney‑in‑fact, Christopher Sefcheck.
Neogen Corporation reported changes to its Board of Directors. William T. Boehm, a director since 2011 who chairs the Audit Committee and serves on the Compensation & Talent Management Committee, has notified the company that he will retire from the Board when his term ends on October 23, 2025. This marks the planned departure of a long-serving director with key committee responsibilities.
The Board has appointed Avi Pelossof as a new Class II director, effective October 24, 2025. He will participate in Neogen’s standard non-employee director compensation program, as previously described in the company’s 2024 proxy statement. The filing highlights his more than 25 years of diagnostics experience, including leadership roles at Immucor Inc. and Alere Inc., where he oversaw a $750 million infectious disease portfolio and the launch of an FDA CLIA-waived point-of-care molecular test.
Gates Capital and related entities report beneficial ownership of 12,793,941 shares of Neogen Corporation common stock, equal to 5.9% of the 217,205,186 shares outstanding as of June 30, 2025. The filing lists Gates Capital Management, L.P.; Gates Capital Management GP, LLC; Gates Capital Management, Inc.; and Jeffrey L. Gates as joint reporting persons, each disclosing shared voting and dispositive power over the same 12,793,941 shares and no sole voting or dispositive power. The statement affirms the shares were acquired in the ordinary course of business and not to influence control of the issuer. The filing includes a joint filing agreement signed August 14, 2025.
A group led by Clarkston Capital Partners, Clarkston Companies and Modell Capital jointly reported beneficial ownership of 14,005,725 shares of Neogen Corporation common stock, representing 6.44% of the company's 217,205,186 outstanding shares used for the calculation. The report breaks ownership down as 5,125,000 shares with sole voting and dispositive power and 8,838,775 (voting) / 8,880,725 (dispositive) shares with shared powers. The filing is presented as a joint Schedule 13G and includes a certification that the securities are held in the ordinary course of business and not with the purpose or effect of changing control.
Neogen Corp. (NEOG) filed its FY-2025 Form 10-K covering the year ended 31 May 2025. The Lansing-based food & animal safety company reports a two-segment structure: Food Safety contributed 71.3 % of FY-25 revenue (vs. 70.9 % FY-24) while Animal Safety supplied 28.7 %. International sales grew to 50.2 % of total. The group employs 2,974 people across 28 countries.
Strategic actions include the April 2025 agreement to divest the global Cleaners & Disinfectants unit and ongoing integration of the 3 M Food Safety Division acquired in Sept 2022 (Reverse Morris Trust). Management still targets cost and revenue synergies but acknowledges impairment charges on the Food Safety reporting unit recorded in Q2 and Q4 FY-25.
Key risk disclosures: (1) Material weaknesses in internal control over financial reporting, mainly ineffective review controls for goodwill valuation; (2) continued challenges merging 3 M’s manufacturing footprint; (3) exposure to tariffs, supply-chain disruption, cybersecurity threats and geopolitical instability; (4) dependence on third-party logistics and single-source suppliers. R&D spend remains at 2-3 % of revenue; no customer represents ≥10 % of sales. Common stock outstanding: 217.2 m shares (30 Jun 2025); public float valued at $2.72 bn (30 Nov 2024).